Pfizer Inc (PFE)

$25.77 -0.89 (-3.34%)
Market Cap 150.33B
Revenue (ttm) 63.63B
Net Income (ttm) 8.03B
EPS (ttm) N/A
PE Ratio 8.16
Forward PE 8.80
Profit Margin 12.62%
Debt to Equity Ratio 0.66
Volume 91,964,912
Avg Vol 48,523,043
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 88%
Beta 0.47
Analysts Sell
Price Target $28.43

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
Willieberich
Willieberich Feb. 4 at 1:22 AM
$PFE stick with the boring stocks ! Like pfe ...thank yourself later ..
0 · Reply
keylimepie2
keylimepie2 Feb. 4 at 1:10 AM
$VKTX Big lesson today: $NVO needs to move fast at the acquisition level. $PFE showed us today that $10 billion doesn’t buy best-in-class. They’ll need to dig much deeper to acquire $VKTX. But $NVO is in a tough position — maybe they wanted to wait for the Phase 3 readout, but after today, can they really take that risk? Other BP players know how vulnerable $NVO is, and it only makes sense that someone could jump in and buy $VKTX, which would seriously threaten $NVO’s market share.
1 · Reply
Sjs360
Sjs360 Feb. 4 at 12:17 AM
$TTD $PFE
0 · Reply
Jack90
Jack90 Feb. 3 at 11:47 PM
$MRK $PFE $JNJ adding some here
0 · Reply
Moparian
Moparian Feb. 3 at 10:54 PM
$SLS $ABBV $PFE
0 · Reply
taxplanr
taxplanr Feb. 3 at 10:50 PM
So the Epstein files show Bill Gates and Jeffrey Epstein planning the COVID pandemic in 2017 $MRNA $BNTX $PFE $NVAX https://www.instagram.com/reel/DUTrmJ4j5WU/?igsh=bGR3aXllZW0waDUx
1 · Reply
Ro_Patel
Ro_Patel Feb. 3 at 10:44 PM
Medicare drug price negotiations to include treatments administered in doctors’ offices, including some for Type 2 diabetes, HIV, cancer & arthritis. These are drugs covered in Medicare Part B. Only retail medications covered by Part D were eligible for the talks during the previous two rounds of discussions. The negotiated prices for the 15 drugs chosen this year will take effect in 2028. About 1.8M beneficiaries used these medications b/n Nov 2024 & Oct 2025, and they accted for about $27B in Medicare Part B & D spending Note: 14 of the drugs, Medicare revs exposed to the negotiations represents only 0% to 3% of the companies’ worldwide 2027 sales. $GILD Biktarvy, a once-daily pill that treats HIV, draws significant sales from Medicare, representing around 8% of Gilead’s est'd global FY27 revs $LLY $ABBV $GSK $PFE
0 · Reply
EingeLTrade
EingeLTrade Feb. 3 at 10:42 PM
💉💊 Pfizer Revenue: $17.56B vs. $16.83B est. ✅ Adj. EPS: $0.66 vs. $0.57 est. ✅ $PFE
0 · Reply
Bazzzigar
Bazzzigar Feb. 3 at 10:34 PM
$PFE incompetent CEO
0 · Reply
sister
sister Feb. 3 at 10:26 PM
$MRNA can always buy cheaper . . . $PFE and $NVO lowr too
0 · Reply
Latest News on PFE
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 3:00 PM EST - 5 hours ago

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Pfizer: Messy Q4 Earnings Mask An Improving Business

Feb 3, 2026, 2:02 PM EST - 6 hours ago

Pfizer: Messy Q4 Earnings Mask An Improving Business

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 7 hours ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO VKTX

Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 12:00 PM EST - 8 hours ago

Silver Surges Over 15%; Pfizer Earnings Top Views

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever

Feb 3, 2026, 11:56 AM EST - 8 hours ago

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

Feb 3, 2026, 11:17 AM EST - 9 hours ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

MRK

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Feb 3, 2026, 10:15 AM EST - 10 hours ago

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Feb 3, 2026, 8:50 AM EST - 11 hours ago

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Feb 3, 2026, 8:17 AM EST - 12 hours ago

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Feb 3, 2026, 7:28 AM EST - 13 hours ago

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Feb 3, 2026, 7:21 AM EST - 13 hours ago

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Feb 3, 2026, 7:18 AM EST - 13 hours ago

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.

Feb 3, 2026, 7:02 AM EST - 13 hours ago

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Feb 3, 2026, 6:57 AM EST - 13 hours ago

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Pfizer beats fourth-quarter profit estimates on strong drug demand

Feb 3, 2026, 6:50 AM EST - 13 hours ago

Pfizer beats fourth-quarter profit estimates on strong drug demand

Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial

Feb 3, 2026, 6:45 AM EST - 14 hours ago

Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

Feb 3, 2026, 6:45 AM EST - 14 hours ago

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

Feb 3, 2026, 6:40 AM EST - 14 hours ago

Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

Feb 2, 2026, 8:42 AM EST - 1 day ago

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

SNY

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Feb 2, 2026, 1:01 AM EST - 1 day ago

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

5 'Safer' Dividend Buys In Barron's 23 Better January Bets Than T-Bill

Jan 31, 2026, 3:47 AM EST - 3 days ago

5 'Safer' Dividend Buys In Barron's 23 Better January Bets Than T-Bill

BBY CAG EQR FRT KEY LYB MAA

Pfizer: Buyer Beware, The Risk Outweighs The Reward

Jan 30, 2026, 10:31 AM EST - 4 days ago

Pfizer: Buyer Beware, The Risk Outweighs The Reward

Why Dividend Stocks Are Essential For What Comes Next

Jan 30, 2026, 7:30 AM EST - 4 days ago

Why Dividend Stocks Are Essential For What Comes Next

AM CAG EPD ET KMI LLY MPLX

Pfizer: A High-Yield Pharma At A Turning Point

Jan 29, 2026, 9:00 AM EST - 5 days ago

Pfizer: A High-Yield Pharma At A Turning Point

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

Jan 27, 2026, 4:52 PM EST - 7 days ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

ABBV LLY

Pfizer vs. Merck Stock And JNJ

Jan 27, 2026, 7:40 AM EST - 7 days ago

Pfizer vs. Merck Stock And JNJ

Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance

Jan 27, 2026, 6:02 AM EST - 7 days ago

Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance

Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)

Jan 23, 2026, 10:33 AM EST - 11 days ago

Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)

December Readers ID'd 9 Ideal 'Safer' Dividends In 40 Dogs

Jan 23, 2026, 9:54 AM EST - 11 days ago

December Readers ID'd 9 Ideal 'Safer' Dividends In 40 Dogs

AGNC AGNCP ARLP ECC EFC ET FBRT

Pfizer CEO Albert Bourla: U.S. drug prices are coming down

Jan 20, 2026, 12:34 PM EST - 14 days ago

Pfizer CEO Albert Bourla: U.S. drug prices are coming down

Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry

Jan 20, 2026, 12:18 PM EST - 14 days ago

Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry

NVO

Novavax enters license agreement with Pfizer for vaccine development

Jan 20, 2026, 7:11 AM EST - 14 days ago

Novavax enters license agreement with Pfizer for vaccine development

NVAX

Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits

Jan 20, 2026, 2:19 AM EST - 14 days ago

Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits

Invesco Equity And Income Fund Q4 2025 Portfolio Positioning And Performance

Jan 19, 2026, 8:10 PM EST - 15 days ago

Invesco Equity And Income Fund Q4 2025 Portfolio Positioning And Performance

BDX DD MSFT ORCL PH Q SLB

MoneyShow's Best Investment Ideas For 2026: Part 7

Jan 19, 2026, 2:20 PM EST - 15 days ago

MoneyShow's Best Investment Ideas For 2026: Part 7

PLD PLG PM QUIK RCAT

Pfizer: Rebound Has Just Started

Jan 16, 2026, 1:08 PM EST - 18 days ago

Pfizer: Rebound Has Just Started

Pfizer: The Most Intriguing Value Play Of 2026

Jan 15, 2026, 8:58 AM EST - 19 days ago

Pfizer: The Most Intriguing Value Play Of 2026

Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Jan 13, 2026, 6:11 AM EST - 21 days ago

Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra

Jan 12, 2026, 6:43 PM EST - 22 days ago

Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra

Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 3:16 PM EST - 22 days ago

Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Jan 10, 2026, 10:00 AM EST - 24 days ago

Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Healthy Returns: What to expect from pharma at the JPM conference

Jan 9, 2026, 12:57 PM EST - 25 days ago

Healthy Returns: What to expect from pharma at the JPM conference

AMGN AZN BMY LLY MRK NVO

Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity

Jan 8, 2026, 8:00 AM EST - 26 days ago

Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity

Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio

Jan 7, 2026, 2:16 PM EST - 27 days ago

Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio

Quant Q&A With Steven Cress

Jan 7, 2026, 7:00 AM EST - 27 days ago

Quant Q&A With Steven Cress

CLS CRDO ET FIX MRK

America's new vaccine doctrine for children replaces data with dogma

Jan 6, 2026, 11:55 AM EST - 4 weeks ago

America's new vaccine doctrine for children replaces data with dogma

MRNA

Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens

Jan 6, 2026, 7:30 AM EST - 4 weeks ago

Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Jan 5, 2026, 10:00 AM EST - 4 weeks ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer 2026: The Reset Year

Jan 2, 2026, 2:52 PM EST - 4 weeks ago

Pfizer 2026: The Reset Year

3 ultra-high-yield stocks to consider for $300 of dividend income in 2026

Dec 31, 2025, 8:37 AM EST - 4 weeks ago

3 ultra-high-yield stocks to consider for $300 of dividend income in 2026

AGNC PFLT

Willieberich
Willieberich Feb. 4 at 1:22 AM
$PFE stick with the boring stocks ! Like pfe ...thank yourself later ..
0 · Reply
keylimepie2
keylimepie2 Feb. 4 at 1:10 AM
$VKTX Big lesson today: $NVO needs to move fast at the acquisition level. $PFE showed us today that $10 billion doesn’t buy best-in-class. They’ll need to dig much deeper to acquire $VKTX. But $NVO is in a tough position — maybe they wanted to wait for the Phase 3 readout, but after today, can they really take that risk? Other BP players know how vulnerable $NVO is, and it only makes sense that someone could jump in and buy $VKTX, which would seriously threaten $NVO’s market share.
1 · Reply
Sjs360
Sjs360 Feb. 4 at 12:17 AM
$TTD $PFE
0 · Reply
Jack90
Jack90 Feb. 3 at 11:47 PM
$MRK $PFE $JNJ adding some here
0 · Reply
Moparian
Moparian Feb. 3 at 10:54 PM
$SLS $ABBV $PFE
0 · Reply
taxplanr
taxplanr Feb. 3 at 10:50 PM
So the Epstein files show Bill Gates and Jeffrey Epstein planning the COVID pandemic in 2017 $MRNA $BNTX $PFE $NVAX https://www.instagram.com/reel/DUTrmJ4j5WU/?igsh=bGR3aXllZW0waDUx
1 · Reply
Ro_Patel
Ro_Patel Feb. 3 at 10:44 PM
Medicare drug price negotiations to include treatments administered in doctors’ offices, including some for Type 2 diabetes, HIV, cancer & arthritis. These are drugs covered in Medicare Part B. Only retail medications covered by Part D were eligible for the talks during the previous two rounds of discussions. The negotiated prices for the 15 drugs chosen this year will take effect in 2028. About 1.8M beneficiaries used these medications b/n Nov 2024 & Oct 2025, and they accted for about $27B in Medicare Part B & D spending Note: 14 of the drugs, Medicare revs exposed to the negotiations represents only 0% to 3% of the companies’ worldwide 2027 sales. $GILD Biktarvy, a once-daily pill that treats HIV, draws significant sales from Medicare, representing around 8% of Gilead’s est'd global FY27 revs $LLY $ABBV $GSK $PFE
0 · Reply
EingeLTrade
EingeLTrade Feb. 3 at 10:42 PM
💉💊 Pfizer Revenue: $17.56B vs. $16.83B est. ✅ Adj. EPS: $0.66 vs. $0.57 est. ✅ $PFE
0 · Reply
Bazzzigar
Bazzzigar Feb. 3 at 10:34 PM
$PFE incompetent CEO
0 · Reply
sister
sister Feb. 3 at 10:26 PM
$MRNA can always buy cheaper . . . $PFE and $NVO lowr too
0 · Reply
Bayside1983
Bayside1983 Feb. 3 at 10:05 PM
$ABBV $MRK $PFE $SLS
0 · Reply
Moparian
Moparian Feb. 3 at 10:03 PM
$PFE $SLS
0 · Reply
cb5000calls
cb5000calls Feb. 3 at 10:02 PM
$SLS 💣 Phase 3 AML trial PASSED interim efficacy + futility, now at 72/80 events with >2x historical OS — this is a de-risked, registration-ready cancer asset entering the endgame. 💥🧬📈 $PFE $MRK $ABBV all on deck right now.
0 · Reply
cb5000calls
cb5000calls Feb. 3 at 9:33 PM
$SLS Two Clinical Stage Cancer Therapies with Minimal Competition MINIMAL!!!! $PFE getting ready to make their move... $XBI $SPY $QQQ
1 · Reply
UgoGreg
UgoGreg Feb. 3 at 9:21 PM
$PFE https://youtu.be/xtKth-XTras
0 · Reply
cb5000calls
cb5000calls Feb. 3 at 9:15 PM
$SLS CEO of $PFE on fox business 20 mins ago literally stated "people can live with cancer like they re living with diabetes".... sounds familiar doesn't it... Literally the pitch our KOLs have been saying, the pitch out CEO has been saying... it all lines up. All the signs are there is you are awake. 💡 Combo that with the Greek minister of health attending both an award dinner for $PFE CEO and then doing an in person tour of $SLS office the next day.... hmmmm I wonder why that took place. $XBI $SPY $QQQ
6 · Reply
BuyHighSellLowGER
BuyHighSellLowGER Feb. 3 at 9:11 PM
$PFE So, what's up $PFE? Something cooking regarding Nipah virus for the summer? I heard smart money is moving to pharma and FFP2 masks doubled in price already?
0 · Reply
lecorb
lecorb Feb. 3 at 9:04 PM
$PFE Pfizer outlines $150B obesity market strategy as VESPER-3 data supports monthly GLP-1 approach https://seekingalpha.com/news/4546513-pfizer-outlines-150b-obesity-market-strategy-as-vesperminus-3-data-supports-monthly-glpminus?mailingid=43911365&messageid=2900&position=rta_news_bankr_hysa_main_0_title&serial=43911365.6556&source=email_2900&utm_campaign=rta-stock-news&utm_content=link-1&utm_source=seeking_alpha&utm_term=43911365.6556
1 · Reply
reyofhope
reyofhope Feb. 3 at 8:59 PM
$PFE now what do we do?
0 · Reply
Twitter70
Twitter70 Feb. 3 at 8:58 PM
$PFE With modest revenue, dwarfing all US major sports combined. See ya tomorrow 🫡 🇺🇸
0 · Reply
cb5000calls
cb5000calls Feb. 3 at 8:57 PM
$SLS $PFE CEO basically let it slip just now on live TV on Fox Business... 🤫😉🤑
6 · Reply
topstockalerts
topstockalerts Feb. 3 at 8:57 PM
Pfizer Earnings Beat Overshadowed by Soft Guidance Pfizer shares fell 3.1% Tuesday despite reporting fourth-quarter results that "handily topped" analyst estimates. While the company is successfully pivoting away from its declining Covid-19 franchise, Wall Street remains cautious regarding its long-term growth trajectory and competitive standing in the obesity market. Financial Performance & Outlook The Beat: Adjusted EPS reached $0.66 (vs. $0.56 expected) on revenue of $17.6 billion (vs. $16.8 billion expected). The Drag: Pfizer reaffirmed its 2026 revenue guidance of $59.5B – $62.5B, which sits at the lower end of analyst expectations ($61.9B). Covid Fade: Revenue for Comirnaty and Paxlovid plummeted 35% and 70%, respectively. CEO Albert Bourla noted that the Covid portfolio is becoming "almost irrelevant" to the company’s future. $PFE
0 · Reply